Paeoniflorin Combined with Neural Stem Cell Transplantation for Parkinson’s Disease: Synergistic Effects of Cell Therapy and Inflammation Regulation
Objective: To investigate the feasibility and efficacy of paeoniflorin (PF) combined with neural stem cell (NSC) transplantation in treating Parkinson's disease (PD). Background: Parkinson's disease…Safety, Tolerability, and Preliminary Efficacy of NouvNeu001 for the Treatment of Advanced Parkinson’s Disease: A Multi-center, Open Label, Phase 1 Study
Objective: This Phase 1 study aims to evaluate the safety, tolerability, preliminary efficacy, and optimal dose of NouvNeu001 for treating mid to late-stage Parkinson’s disease…Continued Evaluation of Bemdaneprocel Following a Phase 1 Study for Parkinson’s Disease: Outcomes Through 3 Years
Objective: To report the safety and clinical outcomes of bemdaneprocel in participants with Parkinson’s disease (PD) through 3 years post transplantation. Background: Bemdaneprocel is an…Targeting IGF2 Signaling for Immune Modulation of Microglia in Parkinson’s Disease
Objective: We propose that IGF2 induces a distinct inflammatory phenotype in macrophages or microglia derived from Parkinson’s disease (PD) patients. Background: Microglia are the resident…NouvNeu001, A Phase 1 Stage Chemically Induced Human Dopaminergic Progenitor Cell Therapy for the Treatment of Mid- to Late-stage Parkinson’s Disease
Objective: To access the efficacy and safety of NouvNeu001 in models of Parkinson’s Disease (PD) and a Phase 1 clinical trial (NCT#06167681). Background: Parkinson's disease…Bioreactor-produced iPSCs-derived Dopaminergic Neuron-containing Neural Microtissues Innervate and Restore Motor Function in a Dose-dependent Manner in a Parkinson Rat Model
Objective: To demonstrate the efficacy of a ready-to-graft 3D neural microtissue product – manufactured at large scale – as a therapeutically viable option to treat Parkinson’s…Safety and Tolerability of Bemdaneprocel in People With Parkinson’s Disease: Results up to 24 Months From a Phase 1 Study
Objective: To report the safety and tolerability of bemdaneprocel in participants with Parkinson’s disease (PD) up to 24 months post transplantation. Background: Bemdaneprocel is an…Motor and Non-Motor Outcomes of Bemdaneprocel in People With Parkinson’s Disease: Results up to 24 Months From a Phase 1 Study
Objective: To describe the effects of bemdaneprocel on motor and non-motor outcomes in participants with Parkinson’s disease (PD) up to 24 months post transplantation (12…Dopaminergic neuronal cell therapy for Parkinson’s Disease: results from a phase 1 study of Bemdaneprocel
Objective: This first-in-human Phase 1 study aims to assess the safety, tolerability, clinical efficacy, and functional imaging measures of bemdaneprocel in subjects with PD. Background:…hUC-MSCs ameliorated CUMS-induced depression by modulating complement C3 signaling-mediated microglial polarization during astrocyte-microglia crosstalk
Objective: To demonstrate whether hUC-MSCs can benefit depressive-like behavior by altering C3/C3a-C3aR signaling to impact microglia polarization in the CUMS model. Background: Major depressive disorder (MDD) has been…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.